Hindustan Bio Sciences Ltd vs Novartis India Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: May 08, 2026

Key Highlights

The Latest Trading Price of Hindustan Bio Sciences Ltd is ₹ 9 as of 08 May 13:58 . The P/E Ratio of Hindustan Bio Sciences Ltd changed from 120.8 on March 2024 to 69.8 on March 2025 . This represents a CAGR of -23.99% over 2 yearsThe P/E Ratio of Novartis India Ltd changed from 65.2 on March 2021 to 19.2 on March 2025 . This represents a CAGR of -21.69% over 5 years The Market Cap of Hindustan Bio Sciences Ltd changed from ₹ 15.38 crore on March 2021 to ₹ 7.16 crore on March 2025 . This represents a CAGR of -14.18% over 5 yearsThe Market Cap of Novartis India Ltd changed from ₹ 1362 crore on March 2021 to ₹ 1938 crore on March 2025 . This represents a CAGR of 7.30% over 5 years The revenue of Hindustan Bio Sciences Ltd for the Dec '25 is ₹ 0.4 crore as compare to the Sep '25 revenue of ₹ 0.01 crore. This represent the growth of 3900% The revenue of Novartis India Ltd for the Dec '25 is ₹ 94.65 crore as compare to the Sep '25 revenue of ₹ 99.73 crore. This represent the decline of -5.09% The ebitda of Hindustan Bio Sciences Ltd for the Dec '25 is ₹ 0.09 crore as compare to the Sep '25 ebitda of ₹ -0.05 crore. This represent the decline of -280% The ebitda of Novartis India Ltd for the Dec '25 is ₹ 31.11 crore as compare to the Sep '25 ebitda of ₹ 33.28 crore. This represent the decline of -6.52% The net profit of Hindustan Bio Sciences Ltd changed from ₹ 0.08 crore to ₹ 0.08 crore over 7 quarters. This represents a CAGR of 0.00% The net profit of Novartis India Ltd changed from ₹ 25.74 crore to ₹ 16.09 crore over 7 quarters. This represents a CAGR of -23.55% The Dividend Payout of Hindustan Bio Sciences Ltd changed from 0 % on March 2021 to 0 % on March 2025 . This represents a CAGR of 0.0% over 5 yearsThe Dividend Payout of Novartis India Ltd changed from 118.09 % on March 2021 to 61.15 % on March 2025 . This represents a CAGR of -12.33% over 5 years .

About Hindustan Bio Sciences Ltd

Hindustan Bio Science Limited was initially incorporated as Garuda Cements Limited in December 1991.
Earlier, it was engaged in cement manufacturing and due to sluggish in the industry, the Company diversified its business into Bio Technology & Pharmaceuticals activities in 2000-01 and the name was changed from Garuda Cements Limited to Hindustan Bio-Sciences Limited.
In 2002, it diversified into software field and subsequently changed its name to Hindustan Bio Sciences Limited on August 8, 2002. The Company engaged in the manufacturing and sale of pharmaceutical products is an integrated firm with diversified businesses in pharmaceutical and biotechnology industries.
The Company initially commenced operations in 1992 by sourcing bulk drugs (APIs) and drug intermediates for the Industry with a wellspring of global suppliers and associates.

About Novartis India Ltd

Novartis India Limited (NIL) is a subsidiary of Swiss giant Novartis, the world's second largest pharmaceutical company was incorporated on 13 December 1947.
The Company is engaged in manufacturing and marketing of drugs, pharmaceutical products and formulations for consumer healthcare and animal healthcare; it operates into four segments such as Pharmaceuticals, Generics, Over the Trade Counter and Animal Health. The origin of Novartis is linked to the origin of three distinct companies namely Geigy, Ciba, and Sandoz.
The history of Geigy goes back to the middle of the 18th century, Ciba was founded around 1860, and Sandoz was set-up in 1886.
In 1970 Ciba and Geigy merged to form Ciba-Geigy Ltd. Sandoz and Ciba-Geigy Ltd continued as separate entities for the next 25 years.
In 1996, in one of the largest corporate mergers in history Sandoz and Ciba-Geigy Ltd.

FAQs for the comparison of Hindustan Bio Sciences Ltd and Novartis India Ltd

Which company has a larger market capitalization, Hindustan Bio Sciences Ltd or Novartis India Ltd?

Market cap of Hindustan Bio Sciences Ltd is 9 Cr while Market cap of Novartis India Ltd is 2,630 Cr

What are the key factors driving the stock performance of Hindustan Bio Sciences Ltd and Novartis India Ltd?

The stock performance of Hindustan Bio Sciences Ltd and Novartis India Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Hindustan Bio Sciences Ltd and Novartis India Ltd?

As of May 8, 2026, the Hindustan Bio Sciences Ltd stock price is INR ₹9.09. On the other hand, Novartis India Ltd stock price is INR ₹1065.45.

How do dividend payouts of Hindustan Bio Sciences Ltd and Novartis India Ltd compare?

To compare the dividend payouts of Hindustan Bio Sciences Ltd and Novartis India Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.